# Exenatide Once-weekly as a Treatment for Multiple System Atrophy

> **NCT04431713** · PHASE2 · COMPLETED · sponsor: **University College, London** · enrollment: 50 (actual)

## Conditions studied

- Multiple System Atrophy

## Interventions

- **DRUG:** Exenatide Pen Injector [Bydureon]

## Key facts

- **NCT ID:** NCT04431713
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-16
- **Primary completion:** 2024-03-22
- **Final completion:** 2024-03-22
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04431713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04431713, "Exenatide Once-weekly as a Treatment for Multiple System Atrophy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04431713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*